Cancer Care


A Multicenter, Randomized, Controlled, Two-Arm, Phase III Study to Evaluate the Safety and Efficacy of MK-3475 Compared to Ipilimumab in Patients with Advanced Melanoma
Principal Investigator (?)
Study Number
This is a three-arm study to evaluate the safety and efficacy of two dosing schedules of
MK-3475 compared to ipilimumab for the treatment of ipilimumab-naïve participants with
unresectable or metastatic melanoma.
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)


View more details from

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.